-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
With the landing of the fifth batch of national boots, foreign giants such as Sanofi, AstraZeneca and Pfizer, as well as a number of domestic companies such as Hengrui, Qilu, and Chia Tai Tianqing, are all facing sales indicators and team structure adjustments after price cuts.
Therefore, even for pharmaceutical companies that traditionally take the OTC market and focus on individual consumers through mass advertising, as consumers’ knowledge level improves and accepts changes in advertising models, and drug advertising is special after all, traditional advertising models will become increasingly difficult
How long will this round of pharmaceutical enterprise reform last? The author believes that the competent authority has strong bargaining power, and the basic law of pharmaceutical enterprise reform may be:
2.
3.
4.
5.
Since "the disease is in the body and the skin", symptomatic treatment is good, and more sales teams should be cut.
However, if domestic enterprises also refer to this response model, they may place themselves in the role of "agent" instead of "entrepreneur"
Looking for a new business model
The past days have passed for many years, and the days to come are still long
Someone complained: "A sip of water is more expensive than a pill
After the emergence of the new rules, whoever first explores a set of feasible and profitable business models may survive
